B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
ATRC
AtriCureDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-28
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+39.8
Score
AI commentary
News tone is mixed-positive: strong Q2 growth, profitability, cash generation, and guidance support are offset by a reported 6.4% after-hours decline and ongoing competition concerns. The available analyst-rating page shows its latest action before the July 23 print, so post-print revision evidence remains unavailable. Social, options, short-interest, and employee data are unavailable; confidence remains moderate rather than high. [Investing.com earnings data](https://www.investing.com/equities/atricure-earnings) [Benzinga analyst ratings](https://www.benzinga.com/quote/ATRC/analyst-ratings)
RankAlpha Sentiment Codex - 2026-07-28
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-10-26eventQ2 beat, guidance support, and volatile post-print reactionHigh impact
Q2 revenue rose 12.8% year over year to $153.6 million, adjusted EBITDA increased 78% to $27.3 million, gross margin reached 77.2%, and net income turned positive. FY2026 revenue guidance is $602-$610 million. A third-party earnings page lists revenue of $153.6 million versus $151.84 million consensus and reports a 6.4% after-hours decline, indicating that the strong print was not immediately rewarded. [#SEC-8K-2026-07-23] [Investing.com earnings data](https://www.investing.com/equities/atricure-earnings)
2026-10-26catalystPFA competition and market-share execution overhangHigh impact
Stored earnings-call highlights report ongoing pressure in minimally invasive ablation from market focus on PFA catheters, plus potential new entrants in appendage management. These risks could limit multiple expansion despite strong reported results. [#PR-EARNINGS-2026-07-24]
2027-07-28catalystClinical-readout optionality from BoxX-NoAF and LeAAPSHigh impact
The company said BoxX-NoAF and LeAAPS are advancing toward clinical data readouts that could inform future cardiac-surgery adoption and growth. A secondary earnings-call summary reports BoxX-NoAF data expected in the first half of 2027, but the available primary filing does not provide a dated milestone. [#SEC-8K-2026-07-23] [#PR-EARNINGS-2026-07-24]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-28 • Updated nightlySource: Internal modelMethodology